You searched for "Epithelial"
Retinal structural features of CMV retinitis
1 October 2016
| Anjali Gupta
|
EYE - Vitreo-Retinal
Confocal adaptive optics (AO) technology has enabled cellular level retinal imaging, including imaging of photoreceptors and blood flow. Adaptive optics scanning laser ophthalmoscopy (AOSLO) is a technology that provides high resolution and high contrast retinal images by correcting ocular aberrations....
Bioengineered human tissue
1 August 2017
| James Hsuan
|
EYE - Pathology, EYE - Oncology
|
ocular, oculoplastic, reconstructive, bioengineering, reconstruction, oculoplastics, orbit
This is a literature review of the current status of tissue engineering related to ocular and oculoplastic reconstructive surgery. The authors describe the process of bioengineering for tissue reconstruction. The aim is to reproduce functional tissue by the use of...
Outcomes of corneal collagen crosslinking (CXL) in pseudophakic bullous keratopathy (PBK)
This was a retrospective non-comparative, interventional case series of 50 eyes in 50 patients with symptomatic PBK who underwent CXL (epithelium-off). Central corneal thickness (CCT), pain score, best corrected visual acuity (BCVA), and corneal transparency were recorded at baseline; at...Topography based keratoconus progression after corneal collagen cross-linking
Case 1 describes a 35-year-old man with progressive keratoconus (PK). His best corrected visual acuity (BCVA) was right 20/80 (-5.25/-7.75 x 85) and left 20/20 (+4.75/-5.00 x 90). His Ks were right 36.32/48.02 D and 41.15/46.41 D. Right central cornea...Inflammatory macular holes
1 April 2014
| Saruban Pasu
|
EYE - General
The authors present a case of closure of a full thickness macular hole in a patient with Behçet’s disease, without surgery. The 23-year-old male they describe presented with a history of recurrent oral aphthous ulcers and a genital ulcer. Ocular...
Outcomes of corneal cross-linking in paediatric patients compared to fellow untreated eyes
This retrospective cohort study evaluated long-term visual, refractive, topographic and safety outcomes of corneal cross-linking (CXL) in patients younger than 18-years-old with keratoconus. The study included all consecutive paediatric patients who underwent epithelium-off CXL treatment for keratoconus at the study...Long-term results of cross-linking treatment for keratoconus
The authors report on the long-term outcomes in a prospective case series of patients with keratoconus undergoing corneal collagen cross-linking (CXL) treatment. Thirty-two patients (40 eyes; mean age 22.5+/-5.5 years) with Grade I, II and III progressive keratoconus were recruited...Neurofibromatosis type 1 features
The aim in this study was to identify the incidence and de nova mutation rate of Neurofibramatosis type 1 (NF1) and describe the ocular and non-ocular findings in a population-based cohort of patients diagnosed over a 30-year period. The study...Effect of long-term scleral contact lenses on corneal topography, tear film and impression cytology in keratoconus
This study of 16 keratoconus patients aimed to investigate the impact of long-term scleral contact lens (ScCL) wear on corneal curvature, corneal thickness, tear film function and ocular surface in patients with keratoconus. Corneal topography, tear osmolarity test, Schirmer 1...Differential diagnosis of retinoblastoma and pseudo retinoblastoma
The authors reviewed the rate of pseudo retinoblastoma (PRB) among cases referred for suspicion of RB at a tertiary referral centre in Turkey and the distribution of PRB cases according to age. This was a retrospective study of 549 patients...Progression of macular atrophy on long-term anti-VEGF therapy for AMD
3 October 2022
| Sofia Rokerya
|
EYE - Vitreo-Retinal
|
Anti-VEGF therapy, Long term, Macular atrophy, neovascular age-related macular degeneration
This retrospective study evaluated the progression of macular atrophy in 53 eyes of 53 patients receiving AntiVEGF Therapy for age-related macular degeneration (nAMD), for at least six years. None of the patients had any macular atrophy (MA) at presentation. MA...